Ciclosporin

[SDL] Ciclosporin Capsule 10 mg, 25 mg, 100 mg

[SDL] Ciclosporin Infusion 50 mg/mL

[SDL] Ciclosporin Oral Solution 100 mg/mL

[MAF] Ciclosporin Eye Drops 0.1%

1. For the treatment of severe keratitis in dry eye disease in patients who fulfil the following criteria:
   • Have a corneal fluorescein staining (CFS) grade of 4 using the modified Oxford scale or equivalent; AND
   • Have an ocular surface disease index (OSDI) greater than or equal to 23; AND
   • Inadequate symptom control using optimised treatment with tear substitutes for at least 3 months

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

19/12/2022 Ciclosporin 0.1% eye drops for treating severe vernal keratoconjunctivitis

[NR] The Ministry of Health’s Drug Advisory Committee has not recommended listing ciclosporin (CsA) 0.1% eye drops on the MOH List of Subsidised Drugs for treating severe vernal keratoconjunctivitis due to the uncertain clinical and cost effectiveness compared with current standard of care.

19/12/2022 Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease

The Ministry of Health’s Drug Advisory Committee has recommended:

• Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease in patients who fulfil the following criteria:

  • Have a corneal fluorescein staining (CFS) grade of 4 using the modified Oxford scale or equivalent; AND

  • Have an ocular surface disease index (OSDI) greater than or equal to 23; AND

  • Inadequate symptom control using optimised treatment with tear substitutes for at least 3 months.

in view of acceptable proposal from the company.

Funding status

[R] Ciclosporin 0.1% eye drops, the only licensed ciclosporin eye preparation registered with the Health Sciences Authority, are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 February 2023.

[NR] MAF assistance does not apply to other strengths or extemporaneous preparations of ciclosporin eye drops.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration